GET DAILY SIGNALSWhy Is Nanobiotix (NBTX) Stock Down -8.38% Today?
Key Takeaways
- Shares of NBTX fell about 8.38% to roughly $28.74 in Monday trading, extending Friday's 7.19% decline into a two-day slide of approximately 15%.
- Primary catalyst: continued de-risking after a bearish analyst note late last week flagged a back-loaded Johnson & Johnson payout structure and a pivotal Phase 3 readout pushed into the first half of 2027.
- Secondary drivers: profit-taking after a highly volatile multi-month rally and lingering unease over weak first-half 2026 results and a recent CFO transition.
- Broader context: the selloff reflects the fragility of a single-asset, pre-revenue biotech story with a binary clinical catalyst still more than a year away.
- What traders are watching next: the NANORAY-312 interim analysis timeline, any updates from Johnson & Johnson on the JNJ-1900 program, and whether the stock stabilizes above recent support levels.
- For deeper data on Price Targets, Earnings, and Forecast for NBTX, visit Tickeron's dedicated pages.
- Explore Trending AI Robots to see AI-driven trading strategies currently outperforming across the market.
Opening Summary
Nanobiotix S.A. (NBTX), a Paris-based late-clinical-stage nanomedicine company developing physics-based cancer therapies, is under pressure in Monday's session. The stock, whose lead candidate NBTXR3 (now designated JNJ-1900) is licensed to Johnson & Johnson's (JNJ) Janssen unit, traded down approximately 8.38% to around $28.74, compared with a prior close of $31.37. The decline marks a continuation of Friday's 7.19% drop, leaving shares roughly 15% below their levels at the end of last week. Markets attributed the renewed weakness to a bearish research note questioning the timing and structure of the company's future economics rather than any new company-specific announcement.
Bearish Analyst Note Pressures the J&J Economics
The sharpest driver of the current slide is a skeptical analyst thesis published late last week. The note argued that Nanobiotix's headline $2.6 billion licensing deal with Johnson & Johnson is heavily back-loaded, with milestone and royalty payments not expected to begin flowing until around 2027. It also emphasized that a separate royalty financing agreement with Healthcare Royalty Partners stands ahead of common shareholders in the capital structure, meaning a fixed share of future JNJ-1900 royalties would be diverted to the lender before reaching equity holders. That framing undercut the "cheap versus the deal value" narrative that had supported the stock and triggered a reassessment of near-term value.
Phase 3 Timeline Uncertainty
Compounding the pressure, the bearish commentary highlighted that the pivotal NANORAY-312 Phase 3 study in head and neck cancer is now guided to report an interim analysis in the first half of 2027. With Johnson & Johnson now controlling both the funding and the timeline of that trial, investors face an extended period with no near-term catalyst to anchor the valuation. For a pre-revenue biotechnology company whose equity value hinges almost entirely on a single asset, a pushed-out binary readout leaves the stock highly sensitive to shifts in sentiment and risk appetite.
Weak Earnings and Leadership Change Linger
The selloff also reflects residual disappointment from Nanobiotix's first-half 2026 results reported in late September. Revenue fell sharply year over year to about €5.6 million, while the net loss widened to roughly €34.3 million, with a per-ADS loss of €0.70 that missed consensus expectations. The company subsequently announced a chief financial officer transition, appointing Arnd Christ in early October. In capital-intensive, cash-burning biotech, abrupt executive turnover can amplify near-term uncertainty, and traders have been weighing that alongside the company's still-solid cash position, which management projects will fund operations into 2029.
Profit-Taking After a Volatile Rally
The magnitude of the move is also consistent with profit-taking. Nanobiotix shares surged dramatically between mid-2025 and mid-2026 before undergoing a correction of more than 50% from their highs, and the name has remained prone to outsized single-day swings. Encouraging clinical updates — including final Phase 1 melanoma data showing a 41.7% objective response rate and median overall survival of roughly 17.8 months — supported a sharp rebound in late October, but the stock has since round-tripped much of that bounce as momentum faded and bearish fundamentals resurfaced.
Market Context and Trading Activity
Trading volume has been elevated during the decline, with Friday's turnover of roughly 236,000 shares well above the three-month average near 149,000 shares. Monday's session opened with continued heavy selling, indicating persistent distribution rather than a single isolated liquidation. Technically, the slide has pushed NBTX below both its 50-day and 200-day moving averages, a bearish development that can reinforce downside momentum. The move appears idiosyncratic to the company rather than a broad biotech rotation, reflecting the stock's concentrated risk profile and its sensitivity to single-asset sentiment.
What Comes Next for NBTX
Looking ahead, the market's focus will remain squarely on the NANORAY-312 Phase 3 program and any guidance from Johnson & Johnson on enrollment, event accrual, and interim analysis timing. Investors will also monitor follow-on data presentations across the JNJ-1900 clinical programs, as well as the company's cash burn trajectory and any further developments in its royalty-financing obligations. Risks remain substantial: a delay or disappointing readout from the pivotal study could weigh heavily on the stock, while positive data or clearer visibility on the J&J economics could support a recovery. Given the wide gap between bearish and bullish analyst expectations, continued volatility is likely.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-driven trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. The featured robots are chosen for their recent strength, giving traders a focused view of algorithmic strategies that are currently adapting well to evolving markets. Explore Trending AI Robots to see which automated approaches are leading right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NBTX in +17.61% Uptrend, rising for three consecutive days on October 27, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NBTX advanced for three days, in 188 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on NBTX as a result. In 80 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for NBTX just turned positive on October 20, 2026. Looking at past instances where NBTX's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for NBTX moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 24 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
NBTX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for NBTX moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
NBTX broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NBTX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-42.878) is normal, around the industry mean (3.104). P/E Ratio (-25.789) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (48.077) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement